PA-BOOMI
Boomi™, the intelligent integration and automation leader, today announced findings of a new global study.1 The IDC InfoBrief, sponsored by IFS and Boomi, reveals that aging, monolithic systems, and a lack of technological understanding at the executive level limit organizational agility and responsiveness to disruptions. The research also identified that having a composable strategy is key for organizations to overcome these challenges.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240613200694/en/
Boomi Research Reveals Composability Essential to Overcome Legacy System Challenges in Enterprises (Graphic: Business Wire)
The study polled over 1,000 C-level respondents across 12 countries in Europe, North America, Middle East, Africa, and Asia Pacific. It found that legacy technology platforms and unfamiliarity with the essential role Application Programming Interfaces (APIs) and composability play in unlocking business data are combining to hamper insights and transformation.
The widely acknowledged risks of not transitioning to composable applications have become even more pressing against the backdrop of current domestic and international upheavals. Recent developments such as Brexit, world issues, and the escalating cost-of-living crises have highlighted the deficiencies of outdated technologies.
While most businesses believe they have withstood the last three years of disruption, leaders report that working capital and inventory imbalances (56%), volatile demand (53%), and unpredictable supply chains (48%) had been their biggest challenges. Respondents also pointed to legacy applications (60%), lack of integration (48%), and inflexible/monolithic applications (43%) as hindering efforts to overcome these challenges - impacting the efficiency with which they can mitigate risks.
The research also revealed that the consequences of outdated technology platforms are being felt by businesses, with reports of limited visibility into operational processes (24%) and poor internal collaboration (18%). These findings suggest that companies struggle to use their data in long-term planning, hampering business agility and the ability to respond to future disruptions effectively.
With more than two-fifths (41%) of organizations lacking a composable strategy, the risk of stagnation and mounting technical debt is glaring. While the value of a composable architecture is well understood by over 70% of the C-suite respondents with business and functional responsibilities, the Board level professionals lag in their understanding - only 19% are clear on the value composability creates. This gulf between senior level executives points to a need for education and clearer business cases that highlight composability’s short, medium, and long-term value.
“This research sends a clear message to executives: To remain competitive, increase agility, and drive productivity across their entire business, composability is key,” said Ed Macosky, Chief Product and Technology Officer at Boomi. “Speed to realizing value requires a strong data foundation and a mature cloud strategy as prerequisites to the adoption of other advanced technologies.”
Encouragingly, 89% of respondents identified API-driven innovation as a key component of composability with over half (51%) pointing to seamless integration between process workflows, and 37% to the importance of single-platform solutions. As well as highlighting the essential role of APIs in creating adaptable and flexible business systems, these findings support the notion that the future of business applications is composable.
In terms of technology preferences, APIs lead the way with 82% of respondents emphasizing their significance, followed by Artificial Intelligence (45%) and Machine Learning (40%). The research indicated that supply chain (51%), procurement (47%), and customer service and support (40%) are the top areas organizations believe they would benefit from application composability.
Despite the recognized importance of composability, the challenges identified in the research highlight the need for broader organizational alignment and clarity in technological direction to fully leverage the advantages of a composable architecture, where APIs play a foundational role.
Nevertheless, the survey data does reveal a significant trend towards investing in composing workflows with multiple products using APIs. Twenty-two percent of respondents reported to be actively pursuing this approach, reflecting a strategic move towards leveraging APIs for integrating diverse systems and applications to drive efficiency and innovation, and eliminate waste.
Macosky concluded: “Inertia in moving to the cloud or formulating a clear composability strategy is likely to prevent businesses from unlocking the full value of AI and machine learning technology. The challenge for organizations now is to realize value pervasively. However, they must overcome considerable barriers, such as the lack of understanding of composability’s value at the executive level and inadequate progression within cloud journeys. It should therefore come as little surprise that the CIO and CTO are the primary champions for composability.”
Additional Resources
- Download the IDC InfoBrief, sponsored by IFS and Boomi, a Global Study of Composability in Enterprise Software and Evolving Business Needs.
- Watch this webinar that explores the findings of the study with guest speakers from IDC, Boomi, and IFS.
About Boomi
Boomi powers the future of business with intelligent integration and automation. As a category-leading, global software as a service (SaaS) company, Boomi celebrates more than 20,000 global customers and a worldwide network of 800 partners. Organizations turn to Boomi’s award-winning platform to connect their applications, data, and people to accelerate digital transformation. For more information, visit boomi.com.
© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
____________________________
1 IDC InfoBrief, sponsored by IFS and Boomi, Global Study of Composability in Enterprise Software and Evolving Business Needs, doc #US51992524, April 2024. In December 2023, over 1,000 senior business decision makers across 12 countries were polled from the manufacturing, energy and utilities, aerospace and defense, construction and engineering, telecoms, and service industries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240613200694/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release
Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
Perma-Pipe International Holdings, Inc. Announces Third Quarter Financial Results23.12.2024 18:43:00 CET | Press release
The Company generated net sales of $41.6 million for the quarter and $113.4 million year-to-dateIncome before income taxes of $5.1 million for the quarter and $13.2 million year-to-dateBacklog of $114.2 million at October 31, 2024, compared to $68.5 million at January 31, 2024 Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the second quarter and fiscal year-to-date period ended October 31, 2024. "Net sales for the third quarter were $41.6 million, a decrease of $4.1 million, as compared to the same quarter last year. Net income attributable to common stock of $2.5 million was an increase of $0.5 million, or 29%, compared to $1.9 million in the third quarter of 2023. For the nine months ended October 31, 2024, net sales of $113.4 million represent an increase of 3% compared to the nine months ended October 31, 2023. The net income attributable to common stock of $7.2 million was an increase of $5.4 million, or 294%, compared to net income at
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom